3 July 2020: Ovarian cancer is the tenth most common cause of cancer among women in the United States and the fifth most common cause of cancer deaths in women across the globe. The incidences of ovarian cancer are high in women aged 55-64 years and the major symptoms are abdominal and pelvic pain, urinary symptoms, bloating, and difficulty in eating. Staging process helps identify ovarian tumors, calculate their size, and detect metastasis and invasion and in order to improve patient survival rates early detection and diagnosis are of utmost significance.
Advanced Imaging Techniques Fuel Segment Growth
Based on cancer type, the ovarian cancer diagnostic market can be segmented into epithelial tumor, germ cell tumor, stromal cell tumor, and others. Based on the location where cancerous cells have developed, the type of ovarian cancer is determined. In 2018, in this segment epithelial tumors remained a forerunner, accounting for over 90% of all ovarian malignancies. Epithelial tumors can be mucinous, serous, endometrioid, or clear cell. Treatment options and survival rates are majorly reduced due to diagnosis of almost seventy to eighty percent of patients in the advanced stage.
Stromal cell and germ cell tumors collectively own a small share of the ovarian cancer diagnostic market. Stromal tumors develop in the tissues responsible for producing hormones such as testosterone, estrogen, and progesterone while in women aged between 20 to 30 years, germ cell tumors are most prevalent.
In 2018, imaging techniques accounted for the largest share of the market due to its extensive usage in cancer staging and increasing importance of early diagnosis of the disease. In order to measure the size and view a tumor internally, transvaginal ultrasound remains the preliminary imaging technique while a CT scan is preferred for cancer staging and is limited to small tumors. In order to detect metastasis and disease severity, more advanced imaging techniques such as PET and MRI scans are used. The market for blood tests is expected to witness a steady growth on account of increasing consumer awareness and technological advancements.
Market Insights
Growth of the market can be attributed to rising prevalence of ovarian cancer and emergence of novel diagnostic products. There is an increasing need to develop novel therapies and new medicines for early and timely diagnosis of this cancer and its treatment. Thus, the global market for diagnostics and therapeutics shows immense potential for growth and development. Rise in funding for ovarian cancer research and increase in number of initiatives by governments are major factors responsible for driving the market growth.
Some of the major companies of the ovarian cancer diagnostic market are GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd.; Johnson & Johnson Services, Inc.; Siemens Healthcare GmbH; AstraZeneca plc; Quest Diagnostics Incorporated.; Bio-Rad Technologies Inc.; Thermo Fisher Scientific; and Abbott.
No comments:
Post a Comment